Therapeutic approaches to the treatment of Alzheimer's disease

Kiyofumi Yamada, Toshitaka Nabeshima

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-β immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease.

Original languageEnglish
Pages (from-to)631-637
Number of pages7
JournalDrugs of Today
Volume38
Issue number9
DOIs
Publication statusPublished - 01-09-2002
Externally publishedYes

Fingerprint

Alzheimer Disease
Cognition
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Amyloid Precursor Protein Secretases
Neurofibrillary Tangles
Estrogen Replacement Therapy
Cholinesterase Inhibitors
Amyloid Plaques
Chelating Agents
Amyloid
Immunization
Anti-Inflammatory Agents
Antioxidants
Metals
Pharmacology
Drug Therapy
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{e61d58e3e48f47b3bc7f22e143ff0931,
title = "Therapeutic approaches to the treatment of Alzheimer's disease",
abstract = "Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-β immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease.",
author = "Kiyofumi Yamada and Toshitaka Nabeshima",
year = "2002",
month = "9",
day = "1",
doi = "10.1358/dot.2002.38.9.696538",
language = "English",
volume = "38",
pages = "631--637",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "9",

}

Therapeutic approaches to the treatment of Alzheimer's disease. / Yamada, Kiyofumi; Nabeshima, Toshitaka.

In: Drugs of Today, Vol. 38, No. 9, 01.09.2002, p. 631-637.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Therapeutic approaches to the treatment of Alzheimer's disease

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-β immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease.

AB - Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-β immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0036750190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036750190&partnerID=8YFLogxK

U2 - 10.1358/dot.2002.38.9.696538

DO - 10.1358/dot.2002.38.9.696538

M3 - Review article

VL - 38

SP - 631

EP - 637

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 9

ER -